Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. We have a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. We are led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com or connect with us on X (formerly Twitter) @SeaportTx
Location: United States, Massachusetts, Boston
Total raised: $325M
Investors 4
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
| 16.09.2024 | ARCH Ventu... | archventur... |
| 27.05.2024 | Sofinnova ... | sofinnova.... |
| 06.02.2025 | Hawktail M... | hawktail.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.11.2024 | Series B | $225M | - |
| 28.04.2024 | Series A | $100M | - |
Mentions in press and media 10
| Date | Title | Description |
| 30.07.2026 | Daily Stock Market Live S&P 500 closes higher Friday as Amazon surges; Dow posts fourth straight winning month: Live updates | The major averages were markedly higher Friday, the last trading session in July, as investors looked past rising bond yields and Amazon shares jumped. The Nasdaq Composite rose 1% to end at 25,373.85, while the S&P 500 added 0.7% to cl... |
| 01.05.2026 | Neuropsychiatry company Seaport Therapeutics debuts on public market with $225M | - |
| 22.09.2025 | ARCH’s Seaport Therapeutics included on Fierce Biotech’s 2025 Fierce 15 list of companies redefining biotech | - |
| 07.11.2024 | Seaport Therapeutics Inks $225M Oversubscribed Series B | BOSTON, MA, Seaport Therapeutics, a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines, announced the closing of an oversubscribed $225 million Series B financing. >> Click here for more fundi... |
| 22.10.2024 | Seaport Therapeutics: $225 Million (Series B) Raised To Advance Novel Neuropsychiatric Medicines | Seaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a... |
| 21.10.2024 | Seaport Therapeutics Closes $225M Series B Financing Round | Seaport Therapeutics, a Boston, MA-based biopharmaceutical company that is developing novel neuropsychiatric medicines, raised $225M in Series B funding. The round, which brought the total amount to $325M, was led by General Atlantic, with ... |
| 28.04.2024 | Seaport Therapeutics Snares $100M in Series A | BOSTON, MA, Seaport Therapeutics, a clinical-stage biopharmaceuticcal company, announced the closing of a $100 million oversubscribed Series A financing round. >> Click here for more funding data on Seaport Therapeutics >> To e... |
| 10.04.2024 | Seaport Therapeutics Raises $100M in Series A Financing | Seaport Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, raised $100M in Series A funding. The round was co-led by Arch Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder ... |
| 09.04.2024 | ARCH funds neuropsychiatry company Seaport Therapeutics, led by the team behind Karuna Therapeutics | - |
| - | Seaport Therapeutics | “Seaport Therapeutics” |